David Charles Waite

Title: David Charles Waite: Innovator in Neuropharmacology

Introduction

David Charles Waite is a notable inventor based in Sandwich, GB. He has made significant contributions to the field of neuropharmacology, particularly through his innovative patents. With a total of 2 patents, Waite has focused on developing compounds that address critical neurological disorders.

Latest Patents

One of Waite's latest patents is related to Quinoxalinediones. This invention pertains to 2,3(1H,4H)-quinoxalinedione derivatives, which serve as selective antagonists of N-methyl-D-aspartate receptors. More specifically, it involves 5-triazolyl-2,3(1H,4H)-quinoxalinedione derivatives and their preparation, compositions, and uses. This invention also outlines a method for treating acute neurodegeneration disorders and chronic neurological disorders. Another significant patent is for a process for the production of indole derivatives. This invention provides a method for producing a compound of formula I by reacting a compound of formula II with a compound of formula III, using a strong base and a palladium(0) catalyst at elevated temperatures in a suitable solvent. Compounds of formula I can be further processed to compounds of formula V, which are useful in treating conditions such as migraines.

Career Highlights

David Charles Waite is currently associated with Pfizer Corporation, a leading global pharmaceutical company. His work at Pfizer has allowed him to contribute to groundbreaking research and development in the field of pharmaceuticals.

Collaborations

Waite has collaborated with notable colleagues, including Alan Stobie and Elisabeth Colette Louise Gautier. These collaborations have further enriched his research and innovation efforts.

Conclusion

David Charles Waite stands out as an influential inventor in the realm of neuropharmacology. His innovative patents and contributions to Pfizer Corporation highlight his commitment to advancing medical science.